AIS Cancer Center at San Joaquin Community Hospital

Summary

AIS Cancer Center at San Joaquin Community Hospital is a medical facility located in Bakersfield, California. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Prostate Cancer, Bladder Cancer and other specialties. AIS Cancer Center at San Joaquin Community Hospital is involved with conducting 46 clinical trials across 209 conditions. There are 4 research doctors associated with this hospital, such as Tianhong Li, Luis Mariscal, Ricardo Salas, and Nicole Gordon.

Top PIs

Clinical Trials running at AIS Cancer Center at San Joaquin Community Hospital

Breast Cancer

Lung Cancer

Pancreatic Cancer

Bladder Cancer

Ovarian Cancer

Prostate Cancer

Breast cancer

Colorectal Cancer

Esophageal cancer

Stomach Cancer

Mindfulness Approaches

for Living After Breast Cancer

NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants will include younger breast cancer survivors (BCS) who were diagnosed with breast cancer at or before age 50 years, have completed their primary cancer treatment (i.e., surgery, radiation, and/or chemotherapy) at least 6 months earlier, and report elevated depressive symptoms.

Recruiting

2 awards

Phase 3

5 criteria

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

Recruiting

2 awards

Phase 3

40 criteria

Blood Sample Collection

for Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

Recruiting

1 award

N/A

9 criteria